A

s the national opioid crisis rages, painkiller manufacturers have raked in profits and earned plaudits by reformulating their opioids in an attempt to deter abuse.

But on Tuesday, a federal advisory panel delivered an extraordinary rebuke to one such product on the market, suggesting that Endo Pharmaceuticals’ efforts to make Opana ER harder to crush ended up making things worse by enabling addicts to inject it.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.